Develop and commercialize ophthalmic medical technologies and pharmaceuticals. Focus on treating glaucoma, corneal disorders, and retinal diseases. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 15% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly below the class average.
There is growth, but not at top-of-the-class tempo.
The stock has been running stronger than the market lately.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
The stock trades below its recent peak — about 12% off the top. A pullback, not a collapse.
Over the last 4 years, sales grew about 15% a year on average.
The company sells $507.4M a year; the problem isn’t sales — it’s costs running above that number.
A loss of $187.7M against $507.4M in annual sales.
At the current pace of spending, the cash lasts about 1.5 years. After that, the company needs to find new money.
On our five-subject report card, GKOS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: GKOS has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.